AstraZeneca (NYSE:AZN) said today that the FDA approved its extended-release formulation of exenatide, Bydureon, for use as an add-on therapy to basal insulin in adults with Type II diabetes.
The company’s once-weekly GLP-1 injectable was first approved in the U.S. in 2012.
Get the full story at our sister site, Drug Delivery Business News.
The post AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval appeared first on MassDevice.
from MassDevice https://ift.tt/2IoKk42
Cap comentari:
Publica un comentari a l'entrada